June 2017

Anthem Updates Insurance Policy for Spinraza

Leave a Comment / Advocacy, Front Page News /

Anthem Inc. recently announced an updated insurance policy for the use of Spinraza (nusinersen) for treatment of spinal muscular atrophy. The revised policy expands criteria for treatment to onset of SMA-associated signs and symptoms before 21 months of age; the previous policy’s criteria for treatment of onset symptoms was 6 months or younger. In 2016, […]

Anthem Updates Insurance Policy for Spinraza Read More »

European Commission Grants Marketing Authorization for Spinraza, Making it First Approved SMA Treatment in the European Union

Leave a Comment / Front Page News /

Biogen announced today that the European Commission (EC) has granted a marketing authorization for Spinraza for the treatment of spinal muscular atrophy (SMA), making it the first approved treatment in the European Union (EU) for SMA. Spinraza was reviewed under the European Medicines Agency’s (EMA) accelerated assessment program, intended to expedite access to patients with

European Commission Grants Marketing Authorization for Spinraza, Making it First Approved SMA Treatment in the European Union Read More »

Scroll to Top